Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL4242588 | 0.97 | CNR1 (0.97) | CNR1CNR2 | |
| SCHEMBL3093252 | 0.97 | CNR1 (1.00) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL4243002 | 0.96 | CNR1 (0.99) | CNR1CNR2 | |
| SCHEMBL4245868 | 0.94 | CNR1 (0.97) | CNR1CNR2 | |
| SCHEMBL4246768 | 0.92 | CNR1 (0.94) | CNR1CNR2 | |
| Sulfuric Acid SCHEMBL4241613 | 0.92 | CNR1 (0.97) | CNR1CNR2 | |
| SCHEMBL3093160 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL29473535 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL4248848 | 0.92 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL4397799 | 0.89 | CNR1 (0.97) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | claimed |
| US-8753875-B2 | Compositions and means for diagnosing microbial infections | STATENS SERUM INSTITUT (DK) | 2014-06-17 | — | — | US | disclosed |
| US-20090068696-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUM INSTITUT | 2009-03-12 | — | — | US | disclosed |
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.